Immunovant, Inc. (IMVT)
| Market Cap | 3.94B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -323.01M |
| Shares Out | 146.78M |
| EPS (ttm) | -2.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 506,149 |
| Open | 26.66 |
| Previous Close | 26.54 |
| Day's Range | 26.58 - 27.01 |
| 52-Week Range | 24.61 - 45.58 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 48.10 (+79.01%) |
| Earnings Date | Nov 7, 2024 |
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for IMVT stock is "Strong Buy." The 12-month stock price forecast is $48.1, which is an increase of 79.01% from the latest price.
News
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Immunovant Provides Update on Graves' Disease Development Program
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported...
Immunovant to Host Graves' Disease Program Update on September 9, 2024
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 20...
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported c...
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advanci...
Immunovant Awarded U.S. Patent for IMVT-1402
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...
Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas
Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech com...
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena
Immunovant continues to show promising developments in anti-FcRn platform's clinical trials and has a strong financial position. Key upcoming catalysts, including Phase 1 data and Phase 2 results, cou...
Immunovant to Present at Upcoming Investor Conferences
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported ...
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced...
Immunovant Announces Pricing of $450 Million Common Stock Financing
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock
Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confidence, and we expect more upside from here. IMVT-1402...
Immunovant Announces Proposed Offering of $300 Million of Common Stock
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce...
Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations
Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experimental autoimmune disease treatment.
Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)
Immunovant's IMVT-1402 shows early promise with dose-dependent IgG reduction and a decent safety profile, rejuvenating the company's drug pipeline. Despite a solid 20.9-month cash runway, escalating R...
Immunovant shares surge after antibody treatment succeeds in early-stage study
Shares of Immunovant surged over 60% in premarket trading on Tuesday, after the drug developer said its antibody treatment succeeded in an early-stage trial.